Biologically active substance, process for preparing the substance and immunoactive composition

• US 4,482,543 A
• Filed: 02/17/1982
• Issued: 11/13/1984
• Est. Priority Date: 02/27/1981
• Status: Expired due to Fees

• Current Assignee: Otsuka Pharmaceutical Factory Incorporated (Otsuka Holdings Company Limited)
• Original Assignee: Otsuka Pharmaceutical Factory Incorporated (Otsuka Holdings Company Limited)
• Inventors: Suzuki, Naoyoshi, Hirose, Tsuneo, Osaki, Humio
• Primary Examiner(s): Phillips, Delbert R.
• Assistant Examiner(s): Moezie, F. T.
• Application Number:
  US06/349,608
• Time in Patent Office: 1,000 Days
• Field of Search: 424/177, 260/112.5 R, 260/112 R
• US Class Current: 514/3.1
• CPC Class Codes: A61K 35/16 Blood plasma; Blood serum umbilical cord blood A61K35/51
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 39/002 Protozoa antigens
• CPC Class Codes: C07K 14/4703 Inhibitors; Suppressors
• CPC Class Codes: C12P 21/005 Glycopeptides, glycoproteins
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
• CPC Class Codes: Y10S 530/806 Antigenic peptides or proteins

Abstract

This invention relates to a biologically active substance which is a glycoprotein having a molecular weight of 3,000 to 5,000 and has activity to inhibit toxoplasma multiplication in homologous cells and heterologous cells.

This invention also relates to a process for preparing the substance, immunoactive compositions containing the substance and use of the substance as a drug.

Claims

1. A biologically active glycoprotein having a molecular weight of 3,000 to 5,000 as determined by a gel filtration method and has activity to inhibit toxoplasma multiplication not only in homologous cells but also in heterologous cells, and further has the following physical and chemical properties;

(a) solubility;

freely soluble in water and practically incoluble in methanol, ethanol, ether, benzene, chloroform and acetone;

(b) ratio of sugar and protein contents;

protein 85-90%, hexosamine 9-13% and hexose 1-2% calculated as glucose;

(c) constituent amino acid of protein portion;

aspartic acid, threonine, serine, glutamic acid, glycine, alanine, cystine, valine, methionine, isoleucine, leucine, tyrosine, phenylalanine, lysine, tryptophan, histidine, arginine and proline;

(d) aspartic acid, glutamic acid and lysine contents in total amino acids;

45 to 65% by weight;

(e) pH;

7.0 to 7.2 (1 W/V % aqueous solution);

(f) thermal stability;

when 1 W/V % aqueous solution of the substance is heated at 60±

0.1°

C. for 30 minutes, the solution still retains the immunoactivity to inhibit toxoplasma multiplication in homologous cells and heterologous cells;

(g) IR absorption;

characteristic absorption at the following wave number (cm^-1);

3600-2900 (strong), 1700-1500 (strong), 1440-1380 (medium), 1160-1080 (medium), and 550 (medium);

(h) UV absorption;

maximum absorption is found at 274-276 nm for 0.1 W/V % aqueous solution;

(i) color reaction;

positive Lowry-Folin process, Ninhydrin reaction, Phenol-sulfuric acid reaction and Elson-Morgan'"'"'s reaction;

(j) color and appearance;

white and amorphous.

2. An immunoactive composition comprising as an active ingredient an immununoactivating effective amount of a biologically active substance in admixture with a pharmaceutically acceptable, non-toxic carrier, the substance being a glycoprotein having a molecular weight of 3,000 to 5,000 as determined by a gel filtration method and having activity to inhibit toxoplasma multiplication not only in homologous cells but also in heterologous cells, and further having the following physical and chemical properties;

(a) solubility;

freely soluble in water and practically insoluble in methanol, ethanol, ether, benzene, chloroform and acetone;

(b) ratio of sugar and protein contents;

protein 85-90%, hexosamine 9-13% and hexose 1-2% calculated as glucose;

(c) constituent amino acid of protein portion;

aspartic acid, threonine, serine, glutamic acid, glycine, alanine, cystine, valine, methionine, isoleucine, leucine, tyrosine, phenylalanine, lysine, tryptophan, histidine, arginine and proline;

(d) aspartic acid, glutamic acid and lysine contents in total amino acids;

45 to 65% by weight;

(e) pH;

7.0 to 7.2 (1 W/V % aqueous solution);

(f) thermal stability;

when 1 W/V % aqueous solution of the substance is heated at 60±

0.1°

C. for 30 minutes, the solution still retains the immunoactivity to inhibit toxoplasma multiplication in homologous cells and heterologous cells;

(g) IR absorption;

characteristic absorption at the following wave number (cm^-1);

3600-2900 (strong), 1700-1500 (strong), 1400-1380 (medium), 1160-1080 (medium), and 550 (medium);

(h) UV absorption;

maximum absorption is found at 274-276 nm for 0.1 W/V % aqueous solution;

(i) color reaction;

positive Lowry-Folin process, Ninhydrin reaction, Phenol-sulfuric acid reaction and Elson-Morgan'"'"'s reaction;

(j) color and appearance;

white and amorphous.

3. Method of inhibiting the multiplication of protozoans in heterologous cells as well as in homologous cells comprising administering an effective amount of the composition as defined in claim 2 to a host infected with the protozoans.

4. Method of inhibiting the multiplication of bacteria comprising administering an effective amount of the composition as defined in claim 2 to a host infected with bacteria.

5. Method of inhibiting the multiplication of viruses comprising administering the composition as defined in claim 2 to a host infected with viruses.

6. Method of treating mouse leukemia P388 comprising administering the composition as defined in claim 2 to a host having said leukemia.

7. An immunoactive composition as defined in claim 2 which is in the form of an injection comprising an immunoactivating effective amount of the biologically active substance in admixture with a pharmaceutically acceptable, non-toxic carrier suitable for administration by injection.

8. An immunoactive composition as defined in claim 2 or 7 which comprises the biologically active substance in an amount effective for inhibiting the multiplication of protozoans.

9. An immunoactive composition as defined in claim 2 or 7 which comprises the biologically active substance in an amount effective for inhibiting the multiplication of bacteria.

10. An immunoactive composition as defined in claim 2 or 7 which comprises the biologically active substance in an amount effective for inhibiting the multiplication of viruses.